Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Overview

Información sobre este estudio

The purpose of this study is to evaluate the effectiveness and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

1. ≥ 40 years of age prior to screening

2. IPF diagnosis ≤ 7 years prior to screening

3. FVCpp ≥ 45%

4. Diffusing capacity for carbon monoxide percent predicted (hemoglobin-adjusted) ≥ 30%
and < 90%

5. Current treatment for IPF with background therapy is allowed, if at a stable dose for
≥ 12 weeks prior to screening

6. If not currently receiving treatment for IPF (either treatment naïve or discontinued
prior treatment), participant must not have taken background therapy for at least 8
weeks prior to screening

Exclusion Criteria:

1. Receiving pharmacologic therapy for pulmonary hypertension

2. Self-reported smoking of any kind (not limited to tobacco)

3. History of malignancy within the past 5 years or ongoing malignancy other than basal
cell carcinoma, resected noninvasive cutaneous squamous cell carcinoma, or treated
cervical carcinoma in situ

4. Hepatic impairment or end-stage liver disease

5. Renal impairment or end-stage kidney disease requiring dialysis

6. Pregnant or lactating female participant

7. Uncontrolled systemic arterial hypertension

8. Receiving any unapproved or investigational agent intended for treatment of fibrosis
in IPF

9. Prior administration of bexotegrast

10. Likely to have lung transplantation during the study (being on transplantation list is
not an exclusion)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 11/7/23. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Andrew Limper, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Samuel Nascak

(507) 422-3403

Nascak.Samuel@mayo.edu

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Augustine Lee, M.D.

Comunícate con nosotros para obtener el estatus más reciente

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publicaciones

Publications are currently not available
.
CLS-20563308

Mayo Clinic Footer